FORM PTO-1449	ORM PTO-1449 U.S. Department of Commerce Rev. 2-32) Patent and Trademark Office		Atty. Docket No.	Serial No.	
(NCV. 2-02)			07-1009-WO-US	10/580,164	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					
			Applicant: Mark Ian Christie		
			Filing Date: May 18, 2006	Group : 1646	

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/P.M./	6,274,711	08/14/01	Golstein, et al			

FOREIGN PATENT DOCUMENTS

Examiner Initial						1	lation
	Document Number	Date	Country	Class	Subclass	Yes	No
						_	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Kotake, et al., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. The Journal of Clinical Investigation, 103:1345-1352 (1999).				
	Chabaud, et al., Contribution of Interleukin 17 to Synovium Matrix Destruction in Rheumatoid Arthritis, Cytokine, 12:1092-1099 (2000).				
EXAMINER	/Prema Mertz/	DATE CONSIDERED 06/17/2008			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.